NASDAQ: STSSSharps Technology Inc Stock
$0.32-0.04 (-11.11%)
Updated Apr 15, 2024
STSS Price
$0.32
Fair Value Price
$0.23
Market Cap
$5.00M
52 Week Low
$0.27
52 Week High
$1.58
P/E
-0.42x
P/B
0.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.84M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.49
Operating Cash Flow
-$9M
Beta
0.71
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
STSS Overview
Sharps Technology Incorporated is a medical device company that manufactures and sells safety syringe products in the U.S. Its 'Sharps Provensa' offering is a smart safety syringe designed to eliminate potentially infectious accidental needlestick injuries Sharps Technology was incorporated in 2017 and is headquartered in Melville, NY.
Zen Score
–
Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how STSS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STSS ($0.32) is overvalued by 37.99% relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
STSS ($0.32) is not significantly undervalued (37.99%) relative to our estimate of its Fair Value price of $0.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
STSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more STSS due diligence checks available for Premium users.
Be the first to know about important STSS news, forecast changes, insider trades & much more!
STSS News
Valuation
STSS fair value
Fair Value of STSS stock based on Discounted Cash Flow (DCF)
Price
$0.32
Fair Value
$0.23
Overvalued by
38.42%
STSS ($0.32) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
STSS ($0.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
STSS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
STSS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.42x
Industry
50.59x
Market
41.94x
STSS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.63x
Industry
3.54x
STSS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STSS's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
STSS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.8M
Liabilities
$3.9M
Debt to equity
0.49
STSS's short-term assets ($4.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STSS's short-term assets ($4.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STSS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.4M
Investing
-$266.9k
Financing
$0.0
STSS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STSS vs Medical Stocks
Sharps Technology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.